- Home
- / Alcon
Alcon
Stock Price
CHF82.2
2024-10-29
Market Capitalization
CHF40.5 B
2024-10-29
Revenue
$10.4 B
FY, 2025
Alcon Summary
Company Summary
- Overview
- Alcon is a company that manufactures surgical and vision care products. It offers eye drops and gels, meibomian gland dysfunction (MGD) treatment systems, advanced technology intraocular lenses (ATIOLs), viscoelastic, ophthalmic microscopes, etc.
- Type
- Public
- Status
- Active
- Founded
- 1945
- HQ
- Geneva, CH | view all locations
- Website
- https://www.alcon.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Ian Bell, President, Global Business & Innovation
Rajkumar Narayanan, President, International
Andrew Pawson, President & GM Global Vision Care Franchise, President & GM, Global Vision Care Franchise
Operating MetricsView all
Countries
60
Sep, 2022
Countries (Customers)
140
Sep, 2022
Business Areas
2
Sep, 2022
LocationsView all
29 locations detected
Geneva, GE HQ
Switzerland
Chemin de Blandonnet 8
Fort Worth, TX
United States
6201 South Fwy
Macquarie Park, NSW
Australia
Suite 1, Level 7/15 Talavera Rd
Wien, Wien
Austria
Am Tabor 44/OG/Top 3. 05
Mechelen, Vlaanderen
Belgium
Building Elephantus, Stationsstraat 55
Mississauga, ON
Canada
2665 Meadowpine Blvd
Alcon Financials
Summary Financials
- Revenue (FY, 2025)
- $10.4B
- Gross profit (FY, 2025)
- $7.2B
- Net income (FY, 2025)
- $980.0M
- Cash (FY, 2025)
- $1.5B
- EBIT (FY, 2025)
- $1.3B
- Enterprise value
- $44.3B